scholarly journals Pheochromocytoma of the Urinary Bladder with Recurrence 10 Years Later

2018 ◽  
Vol 12 (3) ◽  
pp. 164-166 ◽  
Author(s):  
Max Roehmholdt ◽  
John Roehmholdt
Keyword(s):  
Urinary Bladder ◽  
Bladder Tumor ◽  
Partial Cystectomy ◽  
Bladder Tumors

Pheochromocytoma of the bladder is a rare bladder tumor. We report a case of an 80-year-old female who presents with recurrent bladder tumors consistent with pheochromocytoma of the bladder, discovered 10 years post-resection of a prior pheochromocytoma of the urinary bladder. She was treated with partial cystectomy and was found to be symp tom free at 6-month follow-up.

scholarly journals Recurrent Urinary Bladder Paraganglioma

2010 ◽  
Vol 2010 ◽  
pp. 1-3 ◽  
Author(s):  
Ali A. Al-Zahrani
Keyword(s):  
Case Report ◽  
Urinary Bladder ◽  
Histological Examination ◽  
Bladder Tumor ◽  
Imaging Study ◽  
Anterior Wall ◽  
Partial Cystectomy ◽  
Recurrent Lesion ◽  
History Of

A 39-year-old male presented with recurrent attacks of painless haematuria. The patient has a history of partial cystectomy for bladder paraganglioma 10 years prior to the presentation. Imaging study and cystoscopic examination revealed a small anterior wall bladder tumor. The histological examination of the lesion confirmed that it was a urinary paraganglioma. Partial cystectomy was performed to this recurrent lesion. This case report stresses the importance of life-long follow-up of these lesions.

C118 Nuclear matrix protein 22 urinary marker in diagnosing and follow up of urinary bladder tumors

2009 ◽  
Vol 8 (8) ◽  
pp. 696
Author(s):  
T. Smrkolj ◽  
M. Mihelic ◽  
A. Sedlar ◽  
I. Sterle ◽  
J. Osredkar ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Nuclear Matrix ◽  
Matrix Protein ◽  
Bladder Tumors ◽  
Nuclear Matrix Protein ◽  
Urinary Marker

Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome.

1998 ◽  
Vol 16 (4) ◽  
pp. 1298-1301 ◽  
Author(s):  
H W Herr ◽  
D F Bajorin ◽  
H I Scher
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Bladder Tumor ◽  
Tumor Node Metastasis ◽  
Bladder Tumors ◽  
Primary Tumor Site ◽  
Node Metastasis ◽  
Bladder Sparing ◽  
Salvage Cystectomy

PURPOSE To evaluate the 10-year outcome of patients with invasive (T2-3N0M0, staged according to the tumor, node, metastasis system) bladder cancer who responded completely to a combination of methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) chemotherapy followed by bladder-sparing surgery. PATIENTS AND METHODS Of 111 surgical candidates who received neoadjuvant MVAC, 60 (54%) achieved a complete clinical response (T0) on transurethral resection (TUR) of the primary tumor site. Of these, 28 requested follow-up with TUR alone, 15 had a partial cystectomy, and 17 elected a radical cystectomy. The patients were followed up for a median of 10 years (range, 8 to 13 years). RESULTS Of 43 patients who had bladder-sparing surgery, 32 (74%) are alive, which includes 25 (58%) with an intact functioning bladder. Twenty-four patients (56%) developed bladder tumor recurrences from 5 to 96 months, which were invasive in 13 (30%) and superficial in 11 (26%). Thirteen patients required a salvage cystectomy, of whom 6 died, which includes 4 (9%) from a new invasive neoplasm. Of the 17 patients who had radical cystectomy, 11 (65%) are alive. CONCLUSION The majority of patients with invasive bladder tumors who achieve T0 status after neoadjuvant MVAC chemotherapy preserve their bladders for up to 10 years with bladder-sparing surgery. The bladder remains at risk for new invasive tumors. Cystectomy salvages the majority, but not all, of relapsing patients.

scholarly journals Functional Bladder Paraganglioma Treated by Partial Cystectomy

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Amine Hermi ◽  
Hamza Ichaoui ◽  
Aziz Kacem ◽  
Houcem Hedhli ◽  
Faten Gargouri ◽  
...  
Keyword(s):  
Nervous System ◽  
Autonomic Nervous System ◽  
Urinary Bladder ◽  
Neuroendocrine Tumor ◽  
Transurethral Resection ◽  
Partial Cystectomy ◽  
Treatment Modalities ◽  
Rare Tumor ◽  
Bladder Tumors ◽  
Specific Symptoms

Paraganglioma is a rare neuroendocrine tumor that arises from the autonomic nervous system. The urinary bladder paraganglioma accounts for less than 0.1% of bladder tumors. It remains a challenging entity to diagnose and treat due to its rareness and the lack of specific symptoms. Treatment modalities include transurethral resection and cystectomy (partial or total). The authors report a new case of an isolated paraganglioma of the urinary bladder in a 52-year-old female patient that underwent partial cystectomy. This case aims to remind the clinical, histological and therapeutic features of this rare tumor.

scholarly journals CT endoscopy in urinary bladder lesions detection

2007 ◽  
Vol 54 (3) ◽  
pp. 63-66 ◽  
Author(s):  
D.M. Masulovic ◽  
Dj.Z. Saranovic ◽  
D.Z. Sagic ◽  
R.S. Stevic ◽  
R. Maksimovic ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Optimal Estimation ◽  
Bladder Tumors ◽  
Tumor Spread ◽  
Virtual Cystoscopy ◽  
Bladder Distension ◽  
Additional Information ◽  
Virtual Images ◽  
Carcinomatous Lesion

Aim: To evaluate applicability and efficacy CT vurtual cystoscopy in detection of urinary bladder tumors. Material and methods: During the period of 14 months, 17 patients with suspicion or present of some urinary bladder lesions has undergone CT virtual and conventional cystoscopy. After examination, all data were moved to the workstation for interactive endoluminal navigation. After that, radiologist analyzed transversal and virtual images without results of conventional cystoscopy and made conclusion. Results: Results were divided according to their basic clinical application. By using this method, all lesions over 5 mm in size were revealed. In the group of patients that were followed up for urinary bladder tumors, three patients with carcinomatous lesion were revealed. Two tumors of bladder vault that were missed on transversal scan were visualized by virtual cystoscopy. Useful additional information about tumor spread was given in two patient. One tumor inside the bladder diverticulum was detected, that was not seen by conventional cystoscopy. In two patients, endoluminal origin of mass that could not be confirmed by conventional radiologic methods, was determined. Conclusion: CT virtual cystoscopy is useful method and technique that promise a lot, especially in following situations: a) follow up of bladder tumors; b) supplemental estimation of endoscopically hardly accessible regions; c) differential diagnosis between intravesical and exravesical lesions. Optimal estimation offers adequate bladder distension with patient positioned on the back and on the belly and interpretation as well as on transversal and virtual images. .

A HISTOPATHOLOGICAL STUDY OF BLADDER TUMORS

2021 ◽  
pp. 5-7
Author(s):  
Mansi Khamesra ◽  
Lavish Tayal ◽  
Bhavana Garg ◽  
Vijaya Mysorekar
Keyword(s):  
Urinary Bladder ◽  
Bladder Carcinoma ◽  
Bladder Tumor ◽  
Histopathological Study ◽  
Lateral Side ◽  
Urinary Bladder Carcinoma ◽  
Common Symptom ◽  
High Grade ◽  
Bladder Tumors ◽  
Histopathological Type

Background: The bladder is a common site for urinary tract malignancy. Urinary bladder carcinoma is of global concern and the histopathological types and variants are of relevance for their management. This study was carried out to assess the histopathological characteristics of bladder tumors. Materials and methods: The data was collected retrospectively and prospectively to include a total of 140 urinary bladder tumor specimens. Detailed medical records of these subjects were collected, and histopathological examination was performed on the prospective samples. Results: The most common symptom of bladder tumor was hematuria. Cystoscopy results found grossly visible tumor growths in about 76% subjects. Of the total sample, 84% patients underwent transurethral resection of bladder tumor (TURBT) surgery and the rest of them underwent cystectomy. Furthermore, the commonest histopathological type of urinary bladder carcinoma was invasive urothelial carcinoma. About 68.6% patients had high grade tumor. Most tumor growths were present on the lateral side (46.43%). In 52.86% specimens, deep muscles were involved in the tumor. Node involvement was positive in 11 (47.83%) patients. As per TNM classication, majority of the specimens were pT2bN2Mx (26.09%) and pT2bN0Mx (5, 21.74%). Tumors were detected in stage 2 (26.09%), stage 3 (30.43%) and stage 4 (39.13%). Conclusions: The most common symptom observed in patients with urinary bladder carcinoma was hematuria. Cystoscopy results found 75.71% subjects to have grossly visible tumor growths. The major histopathological type of bladder carcinoma was invasive. In 52.86% specimens, deep muscles were involved in the tumor. About 68.6% patients had high grade tumor.

scholarly journals Pediatric bladder neuroblastoma: Case report and literature review

2013 ◽  
Vol 7 (9-10) ◽  
pp. 609 ◽  
Author(s):  
Justin Zhu ◽  
Nathan Hoag ◽  
Paul Gustafson ◽  
Kourosh Afshar ◽  
Andrew MacNeily
Keyword(s):  
Case Report ◽  
Urinary Bladder ◽  
Literature Review ◽  
Pediatric Patient ◽  
Partial Cystectomy ◽  
Gross Hematuria ◽  
Rare Neoplasm ◽  
Rare Diagnosis

Neuroblastoma (NBL) of the urinary bladder is an extremely rare diagnosis, with only 6 cases reported in the literature to date. We report the case of a 3-year-old boy who presented with gross hematuria, and was diagnosed with bladder NBL after partial cystectomy. Two-year follow-up has been unremarkable. This case highlights a rare neoplasm of the urinary bladder in a pediatric patient.

Extraperitoneal and Transperitoneal Laparoscopic Partial Cystectomy for Benign Non-Urothelial Bladder Tumors: An Initial Experience

2014 ◽  
Vol 94 (2) ◽  
pp. 149-155 ◽  
Author(s):  
Ye Lei ◽  
Shiyu Tong ◽  
Xiongbing Zu ◽  
Yuan Li ◽  
Wei He ◽  
...  
Keyword(s):  
Laparoscopic Resection ◽  
Perioperative Complications ◽  
Bladder Wall ◽  
Functional Results ◽  
Partial Cystectomy ◽  
Initial Experience ◽  
Bladder Tumors ◽  
Bladder Dome ◽  
Urothelial Bladder

Objective: This study presents our initial experience with extraperitoneal and transperitoneal laparoscopic partial cystectomy (LPC) in the treatment of benign non-urothelial bladder tumors. Methods: Eleven patients with benign non-urothelial bladder tumors underwent extraperitoneal or transperitoneal LPC. The five cases with tumors located on the anterior/anterolateral bladder wall received the extraperitoneal approach. The six cases with tumors located around the bladder dome or over the posterior bladder wall received the transperitoneal approach. Key perioperative parameters were recorded. Results: All patients underwent laparoscopic resection smoothly without requiring a conversion to a traditional open procedure, and no patient displayed perioperative complications. Pathology showed benign non-urothelial bladder tumors with normal margins in all eleven patients, including five leiomyoma cases, three pheochromocytoma cases, two paraganglioma cases and one inflammatory fibrous histiocytoma case. Follow-up cystoscopy and imaging studies in all eleven patients (mean follow-up period 32 months) revealed neither residual nor local recurrence. Conclusions: LPC is safe and feasible in select patients with benign non-urothelial bladder tumors and yields satisfactory oncological and functional results. Extraperitoneal LPC should be preferred for lesions located on the anterior/anterolateral bladder wall, while transperitoneal LPC should be preferred for lesions around the bladder dome or over the posterior bladder wall.

Adjuvant immunotheraphy in the treatment of superficial multicentric bladder tumors

1992 ◽  
Vol 59 (1_suppl) ◽  
pp. 176-178
Author(s):  
G. Lissoni ◽  
G. Galbiati ◽  
R. Borin ◽  
M. Ferruti ◽  
C. Milani
Keyword(s):  
Natural History ◽  
Bladder Tumor ◽  
Local Treatment ◽  
Intravesical Therapy ◽  
Bacillus Calmette Guerin ◽  
Bladder Tumors ◽  
Adjuvant Immunotherapy ◽  
Superficial Bladder Tumor ◽  
History Of

The authors report their results in adjuvant immunotherapy with B.C.G. after TUR for superficial and multicentric bladder tumors (Ta-T1). After TURB a cycle of intravesical immunotheraphy with 150 mg of BCG (Bacillus Calmette-Guerin) is performed once a week for 6 weeks, ther every 2 weeks for 6 times and finally once a month for 1 year. (16.5 months of treatment). Controls with CTM and cystoscopy are performed periodically. 63 patients have been treated: 20 (60.6%) are free from disease with follow-up of 18–36 months; 87.5% of patients who had BCG as immunotherapy after first TUR for bladder tumor, are free from disease. Comparing their results with experiences reported in literature with Mytomicin and Doxorubicin, the authors think that adjuvant immunotherapy with BCG is actually the best local treatment for these tumors. Some patients (25%) had slight troubles because of therapy but only in 3 cases (9.09%) treatment was stopped. In conclusion intravesical therapy with BCG significantly changes natural history of superficial bladder tumor, increasing the time free from disease (in our experience: 27 months).

Sign in / Sign up

Export Citation Format

Share Document